UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000061857
Receipt number R000070779
Scientific Title Incremental diagnostic value of pericoronary adipose tissue attenuation for the detection of vulnerable plaques
Date of disclosure of the study information 2026/06/10
Last modified on 2026/06/10 13:26:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Incremental diagnostic value of pericoronary adipose tissue attenuation for the detection of vulnerable plaques

Acronym

Pericoronary adipose tissue attenuation for identification of vulnerable plaques

Scientific Title

Incremental diagnostic value of pericoronary adipose tissue attenuation for the detection of vulnerable plaques

Scientific Title:Acronym

Incremental diagnostic value of pericoronary adipose tissue attenuation for the detection of vulnerable plaques

Region

Japan


Condition

Condition

Acute coronary syndrome

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study also aims to evaluate whether adding PCAT attenuation to morphological and physiological CT-derived indices improves the discrimination and reclassification of ACS culprit lesions with plaque rupture.

Basic objectives2

Others

Basic objectives -Others

This study aims to investigate whether pericoronary adipose tissue (PCAT) attenuation provides incremental diagnostic value beyond morphological and physiological CT-derived indices for detecting vulnerable plaques associated with the development of acute coronary syndrome.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Whether the target lesion was identified as the ACS culprit lesion associated with plaque rupture

Key secondary outcomes

Differences in PCAT attenuation between ACS culprit lesions with plaque rupture and non-culprit lesions


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Patients who developed acute coronary syndrome (ACS) due to plaque rupture as defined by percutaneous coronary intervention performed at the participating institutions between January 1, 2016 and December 31, 2025.
2. Patients in whom plaque rupture at the culprit lesion was identified by intravascular imaging, including intravascular ultrasound and/or optical coherence tomography, at the time of ACS.
2. Among the above patients, those who underwent coronary CT between 1 month and 2 years before the onset of ACS.

Key exclusion criteria

1. Patients who developed ACS due to restenosis-related lesions.
2. Patients who underwent coronary artery bypass grafting.
3. Patients with inadequate image quality on coronary CT.

Target sample size

150


Research contact person

Name of lead principal investigator

1st name Takayoshi
Middle name
Last name Toba

Organization

Kobe University Graduate School of Medicine

Division name

Division of Cardiovascular Medicine, Department of Internal Medicine

Zip code

650-0017

Address

7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, Japan

TEL

078-382-5846

Email

taka02222003@gmail.com


Public contact

Name of contact person

1st name Takayoshi
Middle name
Last name Toba

Organization

Kobe University Graduate School of Medicine

Division name

Division of Cardiovascular Medicine, Department of Internal Medicine

Zip code

650-0017

Address

7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo

TEL

078-382-5846

Homepage URL


Email

taka02222003@gmail.com


Sponsor or person

Institute

Others

Institute

Department

Personal name



Funding Source

Organization

None.

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kobe University Hospital Clinical & Translational Research Center

Address

7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan

Tel

078-382-6669

Email

kansatsu@med.kobe-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 06 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 06 Month 10 Day

Date of IRB


Anticipated trial start date

2026 Year 08 Month 01 Day

Last follow-up date

2028 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is a single-center retrospective observational study conducted by Kobe University Hospital as the research institution, using existing information provided by institutions that will only provide such information. The use of existing information is scheduled to begin on August 1, 2026, and the planned sample size is 150 patients.


Management information

Registered date

2026 Year 06 Month 10 Day

Last modified on

2026 Year 06 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000070779